Bio/Pharma News

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

June 28, 2024

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US

June 27, 2024

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.

European Commission Approves Metastatic Colorectal Cancer Monotherapy

June 27, 2024

Fruzaqla was previously approved for use in patients with metastatic colorectal cancer in the US in November 2023.

Sarepta’s Elevidys for Duchenne Muscular Dystrophy Gets Expanded FDA Approval

June 26, 2024

Sarepta Therapeutics received expanded approval from FDA for Elevidys in the treatment of DMD in non-ambulatory patients as ell as ambulatory patients.

argenx Gets FDA Nod for VYVGART Hytrulo in CIDP Indication

June 26, 2024

FDA has approved argenx's VYVGART Hytrulo for a new indication, treating chronic inflammatory demyelinating polyneuropathy.

Bora Pharmaceuticals Acquires Baltimore Manufacturing Facility from Emergent

June 21, 2024

The transaction, announced June 20, follows Bora’s purchase of Minnesota-based Upsher-Smith Laboratories earlier in 2024.

AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients

June 20, 2024

Imfinzi (durvalumab) combined with chemotherapy decreased the risk of disease progression or death by 58% in a 700-patient trial.

FDA Approves Immunoglobulin Therapeutic to Treat Primary Immunodeficiencies

June 18, 2024

Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.

Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases

June 18, 2024

The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.

Lilly Raises Investment in Indiana Site to $9 Billion to Expand API Manufacturing

May 30, 2024

Lilly’s investment increase is intended to boost manufacturing capacity at its Lebanon, Ind., site for APIs used in the production of tirzepatide and other pipeline drug candidates.